Oncoceutics

Oncoceutics, Inc. is a drug development company primarily targeting the most effective inhibitor pathways in human cancer. The company's leadership team represents a group of pharmaceutical development executives with unparalleled success in the industry. At the core of Oncoceutics' scientific and technological foundation is a focus on naturally effective tumor-suppressing pathways in drug research and development. The first lead compound generated by this program is ONC201, a small molecule that exhibits significant anti-tumor activity across many different types of human cancer through a unique mechanism of action. ONC201’s compelling preclinical efficacy and safety profile, along with its favorable chemical properties, offer great potential for safe and meaningful therapeutic benefits for cancer patients in numerous clinical settings. The initial indications for ONC201 are being evaluated in a series of clinical trials at various stages, initiated at major cancer centers worldwide.